Physician profile
Kirk Jacobson
NPI 1093707366
$5,885.93
in general payments reported to CMS, 2019-2025
37 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $577 · 2021: $889 · 2022: $667 · 2023: $1,113 · 2024: $1,397 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.47 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $966.74 | 2019-2025 | |
| Abbott Laboratories | $898.25 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Exact Sciences Corporation | $588.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $469.56 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $429.99 | 2019-2024 | Repatha, Otezla, Prolia |
| Mannkind Corporation | $210.85 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.39 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $162.64 | 2020-2024 | Jardiance, Mounjaro, Lyumjev |
| Nestle Healthcare Nutrition INC. | $159.67 | 2021-2023 | |
| Terumo Medical Corporation | $135.56 | 2024 | Hydropearl |
| Nalu Medical, INC. | $134.72 | 2023-2024 | Nalu Neurostimulation System |
| Stryker Corporation | $133.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $130.56 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $125.25 | 2024-2025 | Zenpep |
| Dexcom, INC. | $123.03 | 2024-2025 | Dexcom G6 Transmitter |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $119.20 | 2019-2024 | Spravato |
| Kowa Pharmaceuticals America, INC. | $118.96 | 2021-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $118.05 | 2019-2021 | |
| Novo Nordisk INC | $105.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $74.61 | 2021-2024 | |
| Glaxosmithkline, LLC. | $71.75 | 2024-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Edwards Lifesciences Corporation | $62.63 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Allergan, INC. | $56.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $49.68 | 2021-2025 | Eliquis |
| Celgene Corporation | $37.03 | 2022-2023 | Eliquis |
| Medtronic, INC. | $27.20 | 2025 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $26.75 | 2021 | |
| Eisai INC. | $21.90 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.16 | 2022 | |
| Blueprint Medicines Corporation | $19.44 | 2023 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $19.39 | 2023 | |
| Axsome Therapeutics, INC. | $18.80 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $18.36 | 2023 | Rexulti, Abilify Maintena |
| Biohaven Pharmaceuticals, INC. | $14.84 | 2021 | |
| Astellas Pharma US INC | $14.18 | 2021 | |
| Daiichi Sankyo INC. | $12.60 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.54 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.